OSTEOS

Risedronic acid is a third generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease Label 1, 2.

It functions by preventing resorption of bone Label 1.

Risedronic acid is indicated for the treatment of osteoperosis in men, treatment of Paget's disease, treatment and prevention of osteoperosis in postmenopausal women, and treatment and prevention of glucocorticoid-induced osteoperosis Label.

Risedronate is a pyridine-based bisphosphonate that inhibits bone resorption caused by osteoclasts Label.

Oral bioavailability is 0.63% and maximum absorption is approximately 1 hour after dosing Label.

Administration half and hour before a meal reduces bioavailability by 55% compared to fasting and dosing 1 hour before a meal reduces bioavailability by 30% Label.

Risedronic acid is not likely not metabolized before elimination Label.

P-C-P group of bisphosphonates is resistant to chemical and enzymatic hydrolysis preventing metabolism of the molecule 1.

Risedronate is excreted by the kidneys and the unabsorbed dose is eliminated in the feces Label.

The initial half life of risedronic acid is approximately 1.5 hours 3, with a terminal half life of 561 hours Label.

Mean renal clearance was 52 mL/min and mean total clearance was 73 mL/min Label.

Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.

View sample adverse effects data in our new Data Library! See the data Improve decision support & research outcomes with our structured adverse effects data.

In clinical trials, over 10% of patients experienced back pain, arthralgia, abdominal pain, and dyspepsia Label.

Less commonly, patients experience angioedema, generalized rash, bullous skin reactions, iritis, and uveitis Label.

Patients experiencing an overdose may experience a decrease in serum calcium and phosphorus Label.

Patients can be given milk or antacids to bind the drug and reduce its absorption Label.

In more severe cases, patients may require gastric lavage and intravenous calcium Label.

A lethal dose in rats is equivalent to 320-620 times the human dose based on surface area Label.

For external use only.

Do not use more than one acne product at a time.

After area is wet with

Blemfree™ Cleansing Wash Concentrate has foamed, tap Blemfree™ Cleansing Spheres with fingertips and massage in small circles for 60 seconds.

Proceed to rinse step.